Table 3.

Correlation of HDAC mRNA expression with treatment of GC patients.

HDACs	Treatment	Cases	HR (95%CI)	P value
HDAC1	Surgery alone	393	0.69 (0.51–0.93)	.013∗
	5 FU based adjuvant	157	2.03 (1.36–3.05)	.00048∗
HDAC2	Surgery alone	393	0.88 (0.66–1.18)	.39
	5 FU based adjuvant	157	0.39 (0.15–1.01)	.046∗
HDAC3	Surgery alone	393	0.83 (0.62–1.12)	.22
	5 FU based adjuvant	157	1.65 (1.16–2.35)	.0052∗
HDAC4	Surgery alone	393	1.59 (1.19–2.12)	.0016∗
	5 FU based adjuvant	157	1.9 (0.74–4.86)	.17
HDAC5	Surgery alone	393	1.54 (1.15–2.05)	.0032∗
	5 FU based adjuvant	157	1.61 (0.63–4.1)	.31
HDAC6	Surgery alone	393	1.36 (0.98–1.87)	.062
	5 FU based adjuvant	157	1.63 (1.13–2.36)	.009∗
HDAC7	Surgery alone	393	1.5 (1.09–2.04)	.011∗
	5 FU based adjuvant	157	1.39 (0.98–1.97)	.062
HDAC8	Surgery alone	393	1.43 (1.07–1.92)	.016∗
	5 FU based adjuvant	157	2.08 (0.78–5.5)	.13
HDAC9	Surgery alone	393	1.51 (1.1–2.08)	.011∗
	5 FU based adjuvant	157	0.64 (0.45–0.91)	.012∗
HDAC10	Surgery alone	393	1.36 (0.97–1.9)	.074
	5 FU based adjuvant	157	3.43 (0.78–15)	.082
HDAC11	Surgery alone	393	1.36 (0.99–1.85)	.054
	5 FU based adjuvant	157	3.05 (1.06–8.79)	.031∗

5 FU = 5 fluorouracil; GC = gastric cancer; HDACs = histone deacetylases; HR = hazard ratio.

^∗P value < .05.